Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health Care Reform's Impact Reflected In Pharma's Q1 Results

Executive Summary

President Obama had barely put his signature to the new health care reform law when its impact on biopharma became clear. With Lilly in the lead, a parade of companies posted first quarter financial results which underscored a key point for the industry: it is bearing costs of the new law immediately, but won't reap the benefits for several years

You may also be interested in...

Amgen Quarterly Report: Profits Up, HCR Fears Down

Amgen says health care reform will trim its sails, but it's not much compared to the blow it took from the ESA safety problems.

Abbott Lowers 2010 Guidance Due To U.S. Health Care Reform; Q1 Sales Rise 14.6%

Abbott adjusted its previous 2010 earnings per share guidance by $0.07 to range from $4.13 to $4.18.

Novartis Sales Rise 25%; Jimenez Talks Up U.S. Commercial Restructuring In Interview

Novartis sees no need to change its 2010 guidance based on health care reform and maintains its forecast for mid-single-digit growth.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts